Old Web
English
Sign In
Acemap
>
Paper
>
DOP39 Utilization and sustainability of biologics in UC - A nationwide study from the epi-IIRN
DOP39 Utilization and sustainability of biologics in UC - A nationwide study from the epi-IIRN
2021
Ohad Atia
D Yogev
C Friss
Gili Focht
Esther Orlanski-Meyer
R Magen Rimon
N Ledderman
S Greenfeld
Revital Kariv
Y Loewenberg Weisband
Hagit Gabay
Daniel Nevo
E. Matz
Y. Gorelik
Yehuda Chowers
Iris Dotan
Dan Turner
Keywords:
Internal medicine
Infliximab
Medicine
Irritable bowel syndrome
Vedolizumab
Inflammatory bowel disease
Combined Modality Therapy
Neoadjuvant therapy
Biological response modifiers
Adalimumab
Correction
Source
Cite
Save
Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI
[]